My #1 Pre IPO Trade for 2025 – NAME and TICKER

One tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...

Tony Ho Biography and Net Worth

VP of CRISPR Therapeutics

Dr. Tony W. Ho M.D. serves as Executive Vice President - Research and Development of the Company. Prior to joining our company, Dr. Ho held a number of roles at AstraZeneca between 2012 and 2017, where he most recently was Senior Vice President and Head of Oncology Integration and Innovation. Before that, he was Vice President and Global Medicine Leader, where he led the development and commercialization of two key drugs for AstraZeneca – Lynparza, a PARP inhibitor for ovarian cancer and Imfinizi (anti-PD-L1), AstraZeneca’s first immuno-oncology drug for bladder cancer. Prior to joining AstraZeneca, Dr. Ho was the Neurology and Ophthalmology Clinical Section Head at Merck Research Laboratories, Merck & Co., Inc. Earlier in his career, Dr. Ho was the co-founder and Chief Scientific Officer of Neuronyx, Inc., a regenerative medicine company. Dr. Ho completed his B.S. in Electrical Engineering at the University of California, Los Angeles, and received his M.D. from the Johns Hopkins University School of Medicine.

What is Tony W. Ho's net worth?: The estimated net worth of Tony W. Ho is at least $1.92 million as of June 23rd, 2020. Dr. Ho owns 40,676 shares of CRISPR Therapeutics stock worth more than $1,922,348 as of November 21st. This net worth approximation does not reflect any other assets that Dr. Ho may own. Learn More about Tony W. Ho's net worth.
How do I contact Tony W. Ho?: The corporate mailing address for Dr. Ho and other CRISPR Therapeutics executives is BAARERSTRASSE 14, ZUG V8, CH-6300. CRISPR Therapeutics can also be reached via phone at (141) 561-3277 and via email at [email protected]. Learn More on Tony W. Ho's contact information.
Has Tony W. Ho been buying or selling shares of CRISPR Therapeutics?: Tony W. Ho has not been actively trading shares of CRISPR Therapeutics within the last three months. Learn More on Tony W. Ho's trading history.
Who are CRISPR Therapeutics' active insiders?: CRISPR Therapeutics' insider roster includes Bradley Bolzon (Director), Julianne Bruno (COO), Kurt Emster (Director), Tony Ho (VP), James Kasinger (General Counsel), Lawrence Klein (COO), Samarth Kulkarni (CEO), Rodger Novak (President), Raju Prasad (CFO), and Michael Tomsicek (CFO). Learn More on CRISPR Therapeutics' active insiders.
Are insiders buying or selling shares of CRISPR Therapeutics?: In the last year, insiders at the sold shares 14 times. They sold a total of 192,740 shares worth more than $12,514,312.47. The most recent insider tranaction occured on November, 11th when CEO Samarth Kulkarni sold 30,000 shares worth more than $1,668,600.00. Insiders at CRISPR Therapeutics own 4.1% of the company. Learn More about insider trades at CRISPR Therapeutics.
Information on this page was last updated on 11/11/2024.

Tony W. Ho Insider Trading History at CRISPR Therapeutics

Tony W. Ho Buying and Selling Activity at CRISPR Therapeutics

CRISPR Therapeutics Company Overview

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Today's Range

Now: $46.16

$45.51

$47.21

50 Day Range

MA: $47.96

$44.90

$54.86

2 Week Range

Now: $46.16

$43.42

$91.10

Volume

689,672 shs

Average Volume

1,481,154 shs

Market Capitalization

$3.94 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.67

My #1 Pre IPO Trade for 2025 – NAME and TICKER

From Wyatt Investment Research | Ad

The Next SpaceX Pre-IPO